Clinical Trial Update: Application of a Novel Biomarker Based on Plasma cfDNA Assay in the Early Diagnosis of Prostate Cancer

View source ↗

Summary

A clinical trial is evaluating a novel plasma cfDNA biomarker for early diagnosis of prostate cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Prostate Cancer | Status: RECRUITING